Elon, Inc: Elon’s Bad Trip

We here at Big Take are big fans of our colleagues and friends over at the Elon, Inc podcast from Businessweek, hosted by David Papadopoulos. Please enjoy this episode, and hop on over to subscribe to their feed if you like what you hear!
----

Were we talking about almost any other executive, the report by the Wall Street Journal over the weekend about Elon Musk’s alleged drug use would have qualified as a bombshell. The article contends the chief executive of SpaceX and Tesla has used a collection of substances. This, according to the Journal’s unidentified sources, has caused consternation within Musk’s companies, with Tesla board members and SpaceX executives privately expressing concerns that the alleged drug use may be making Musk unreliable and erratic.

But it’s not clear that many people, either inside or outside Musk’s companies, are genuinely worried. Musk mostly laughed off the report, offering a jokey response suggesting that  any drugs he was taking should be seen as performance enhancers and noting that he’d passed government-mandated drug tests “after that one puff on Rogan”—a reference to a 2018 interview with Joe Rogan during which he smoked marijuana. Investors have been largely unmoved by all of this, partly because during the period that Musk is alleged to have indulged in illicit substances, he also made them a great deal of money. And Musk has mostly gone back to his regular schedule of boosting conspiracy theories proffered by election deniers, white nationalists and other assorted right wing influencers.

On this episode, we are joined by Loren Grush, a Bloomberg aerospace reporter and author of the NASA history, The Six, to discuss why these drug allegations haven’t hurt Musk and why a labor dispute involving SpaceX employees might be a bigger threat in the long run.

See omnystudio.com/listener for privacy information.